Orthofix Medical (NASDAQ:OFIX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Orthofix Medical (NASDAQ:OFIX) announced its quarterly earnings data on Wednesday. The medical device company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02, FiscalAI reports. The business had revenue of $210.93 million during the quarter, compared to analyst estimates of $209.28 million. Orthofix Medical had a negative return on equity of 13.44% and a negative net margin of 7.27%.

Here are the key takeaways from Orthofix Medical’s conference call:

• Q2 net sales grew 5% on a pro forma constant-currency basis, led by 10% growth in global spine fixation and 11% growth in global limb reconstruction. Biologics stabilized to approximately flat year over year after significant declines in 2025.
• CMS restored Medicare reimbursement for bone-growth stimulators retroactive to May 18, providing an estimated $12 million benefit and improving visibility for Therapeutic Solutions in the second half. The company also launched the redesigned AccelStim 2.0 device.
• Orthofix raised its 2026 outlook to $845 million-$855 million in net sales and $95 million-$98 million in adjusted EBITDA. The increase includes reimbursement recovery and approximately $15 million of European distributor inventory purchases tied to MDR certification work, with most of that revenue expected in Q4.
• Smaller U.S. spine distributors, representing roughly 20% of spine sales, continue to underperform due primarily to weak asset utilization and channel productivity. Management expects the softness to persist through year-end and is considering consolidating or exiting weaker relationships, which implies only about 2%-3% core growth in the second half excluding the European order.
• The company is investing in clinical evidence for biologics products and pursuing a potential diabetic-foot-ulcer indication for its limb-reconstruction technologies. Orthofix also completed initial VIRATA minimally invasive spine cases and expects a full market launch late in the fourth quarter.

Orthofix Medical Trading Down 14.6%

Orthofix Medical stock opened at $10.42 on Thursday. Orthofix Medical has a one year low of $8.85 and a one year high of $16.99. The company’s fifty day moving average price is $10.48 and its two-hundred day moving average price is $11.75. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.87 and a quick ratio of 1.76. The company has a market capitalization of $421.20 million, a price-to-earnings ratio of -6.90 and a beta of 0.68.

Analysts Set New Price Targets

OFIX has been the topic of several research reports. Stifel Nicolaus dropped their target price on Orthofix Medical from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. Canaccord Genuity Group lowered their price target on Orthofix Medical from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 21st. TD Cowen restated a “hold” rating on shares of Orthofix Medical in a report on Thursday, May 21st. Barrington Research raised their price objective on shares of Orthofix Medical from $15.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday, July 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $16.00.

Key Headlines Impacting Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Orthofix reported second-quarter revenue of $210.9 million, above analysts’ $209.3 million estimate. Adjusted earnings were reported at $0.07 per share, exceeding the Zacks consensus estimate for a $0.03 loss, while the company’s reported GAAP loss was $0.39 per share, modestly better than the expected $0.41 loss. Orthofix Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company forecast 2026 net sales of $845 million to $855 million, ahead of the approximately $841 million analyst consensus. Management said the outlook is supported in part by a $15 million European MDR-related inventory order. Orthofix 2026 Net Sales Forecast
• Neutral Sentiment: The earnings beat was accompanied by a still-negative GAAP net margin of 7.27% and negative return on equity, indicating that Orthofix remains unprofitable despite revenue growth and better-than-expected adjusted results. Orthofix Earnings Report
• Negative Sentiment: The market’s negative reaction suggests investors may have viewed the earnings quality and profitability outlook as insufficient, particularly because the company continues to post GAAP losses. The $15 million MDR-related order may also be seen as a one-time or nonrecurring boost rather than evidence of broad-based demand acceleration.

Insider Buying and Selling at Orthofix Medical

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,670 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $9.38, for a total value of $34,424.60. Following the completion of the sale, the insider owned 66,330 shares of the company’s stock, valued at $622,175.40. The trade was a 5.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its position in Orthofix Medical by 67.7% during the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock worth $333,000 after purchasing an additional 8,241 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Orthofix Medical by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock valued at $335,000 after purchasing an additional 1,213 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Orthofix Medical in the first quarter valued at approximately $1,076,000. Strs Ohio bought a new position in shares of Orthofix Medical in the first quarter valued at approximately $150,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Orthofix Medical by 15.6% in the second quarter. JPMorgan Chase & Co. now owns 193,549 shares of the medical device company’s stock worth $2,158,000 after buying an additional 26,123 shares during the last quarter. 89.76% of the stock is owned by institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.